Inherent and iatrogenic immune defects in hairy cell leukemia: revisited

Bibliography

• Kraut EH. Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003;16(1):33-40
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice. Expert Opin Pharmacother 2008;9(9):1481-94
   PubMed Web of Science ®Google Scholar
• Mackowiak PA, Demian SE, Sutker WL, Infections of hairy cell leukemia. Clinical evidence of a pronounced defect in cell-mediated immunity. Am J Med 1980;68(5):718-24
   PubMed Web of Science ®Google Scholar
• Golomb HM, Hadad LJ. Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 1984;16(4):393-401
   PubMed Web of Science ®Google Scholar
• Jacobs RH, Vokes EE, Golomb HM. Second malignancies in hairy cell leukemia. Cancer 1985;56(6):1462-7
   PubMed Web of Science ®Google Scholar
• Nielsen B, Braide I, Hasselbalch H. Evidence for an association between hairy cell leukemia and renal cell and colorectal carcinoma. Cancer 1992;70(8):2087-90
   PubMed Web of Science ®Google Scholar
• Federico M, Zinzani PL, Frassoldati A, Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002;20(3):638-46
   PubMed Web of Science ®Google Scholar
• Paltiel O, Adler B, Barchana M, A population-based study of hairy cell leukemia in Israel. Eur J Haematol 2006;77(5):372-7
   PubMed Web of Science ®Google Scholar
• Hisada M, Chen BE, Jaffe ES, Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007;99(3):215-22
   PubMed Web of Science ®Google Scholar
• Au WY, Klasa RJ, Gallagher R, Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998;92(4):1160-4
   PubMed Web of Science ®Google Scholar
• Steis RG, Marcon L, Clark J, Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988;71(5):1304-9
   PubMed Web of Science ®Google Scholar
• Burton J, Kay NE. Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 1994;8(1):92-6
   PubMed Web of Science ®Google Scholar
• Moss PA, Gillespie G. Clonal populations of T-cells in patients with B-cell malignancies. Leuk Lymphoma 1997;27(3-4):231-8
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans JC, Kester MG, Melenhorst JJ, Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood 1996;87(9):3795-802
   PubMed Web of Science ®Google Scholar
• Xie XY, Sorbara L, Kreitman RJ, Development of lymphoproliferative disorder of granular lymphocytes in association with hairy cell leukemia. Leuk Lymphoma 2000;37(1-2):97-104
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Kester MG, van deCorput L, Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia. Blood 1998;91(11):4224-31
   PubMed Web of Science ®Google Scholar
• Arons E, Sorbara L, Raffeld M, Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunol Immunother 2006;55(9):1100-10
   PubMed Web of Science ®Google Scholar
• van de Corput L, Falkenburg JH, Kester MG, Impaired expression of CD28 on T cells in hairy cell leukemia. Clin Immunol 1999;93(3):256-62
   PubMed Web of Science ®Google Scholar
• Bigda J, Mysliwska J, Baran W, Interleukin 2- and interferon alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia. Leuk Lymphoma 1993;9(4-5):371-6
   PubMed Web of Science ®Google Scholar
• Lauria F, Rondelli D, Raspadori D, Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Eur J Haematol 1994;52(1):16-20
   PubMed Web of Science ®Google Scholar
• Netea MG, Hoitink O, Kullberg BJ, Defective interferon-gamma production in patients with hairy cell leukaemia. Neth J Med 2008;66(8):340-34
   PubMed Web of Science ®Google Scholar
• Porzsolt F, Janik R, Heil G, Deficient IFN alpha production in hairy cell leukemia. Blut 1986;52(3):185-90
   PubMedGoogle Scholar
• Bourguin-Plonquet A, Rouard H, Roudot-Thoraval F, Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia. Br J Haematol 2002;116(3):595-7
   PubMed Web of Science ®Google Scholar
• Mackowiak PA, Demian SE, Sutker WL, Infections of hairy cell leukemia. Clinical evidence of a pronounced defect in cell-mediated immunity. Am J Med 1980;68(5):718-24
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Machii T, Tokumine Y, Hairy cells from hairy cell leukemia patients presenting with pronounced polyclonal hypergammaglobulinemia secrete a factor enhancing IgG synthesis. Clin Immunol Immunopathol 1993;66(3):212-8
   PubMedGoogle Scholar
• Dasanu CA, Alexandrescu DT. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed 2007;9(4):35
   PubMedGoogle Scholar
• Farcet JP, Weschsler J, Wirquin V, Vasculitis in hairy-cell leukemia. Arch Intern Med 1987;147(4):660-4
   PubMed Web of Science ®Google Scholar
• Westbrook CA, Golde DW. Autoimmune disease in hairy-cell leukaemia: clinical syndromes and treatment. Br J Haematol 1985;61(2):349-56
   PubMed Web of Science ®Google Scholar
• Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 1995;25(2):134-42
   PubMed Web of Science ®Google Scholar
• Mey U, Strehl J, Gorschlüter M, Advances in the treatment of hairy-cell leukaemia. Lancet Oncol 2003;4(2):86-94
   PubMed Web of Science ®Google Scholar
• Gidron A, Tallman MS. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 2006;47(11):2301-7
   PubMed Web of Science ®Google Scholar
• Lauria F, Rondelli D, Zinzani PL, Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia 1997;11(5):629-32
   PubMed Web of Science ®Google Scholar
• Schirmer M, Hilbe W, Geisen F, T cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine. Acta Haematol 1997;97(3):180-3
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16(9):3007-15
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kurzrock R, Freireich EJ, 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83(10):2906-11
   PubMed Web of Science ®Google Scholar
• Bastie JN, Cazals-Hatem D, Daniel MT, Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma 1999;35(5-6):555-65
   PubMed Web of Science ®Google Scholar
• Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83(12):3672-81
   PubMed Web of Science ®Google Scholar
• Spiers AS. Pentostatin (2prime prime or minute-Deoxycoformycin): clinical pharmacology, role in cancer chemotherapy, and future prospects. Am J Ther 1995;2(3):196-216
   PubMedGoogle Scholar
• Higman M, Vogelsang GB, Chen A. Pentostatin–pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother 2004;5(12):2605-13
   PubMed Web of Science ®Google Scholar
• Kraut EH, Neff JC, Bouroncle BA, Immunosuppressive effects of pentostatin. J Clin Oncol 1990;8(5):848-55
   PubMed Web of Science ®Google Scholar
• Ho AD, Männel DN, Wulf G, Long-term effects of 2′-deoxycoformycin treatment on cytokine production in patients with hairy cell leukemia. Leukemia 1990;4(8):584-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Stawinski GV, Yu PB, Love SD, Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Clin Immunol 2001;98:175-9
   PubMed Web of Science ®Google Scholar
• Van der Kolk LE, Baars JW, Prins MH, Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-9
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;346(4):241-7
   Google Scholar
• Kreitman RJ, Pastan I. Immunobiological treatments of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003;16(1):117-33
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Stoica-Mustafa E, Herlea V, New therapies for patients with hairy cell leukemia at a glance: comprehensive review article with an illustrative case. Ann Fundeni Hosp 2005;10(3-4):75-8
   Google Scholar